Assistance Publique-Hôpitaux de Paris, Service de Néphrologie, Hôpital Necker Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.
Clin J Am Soc Nephrol. 2011 Oct;6(10):2429-38. doi: 10.2215/CJN.01220211. Epub 2011 Aug 25.
UMOD mutations cause familial juvenile hyperuricemic nephropathy (FJHN) and medullary cystic kidney disease (MCKD), although these phenotypes are nonspecific.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We reviewed cases of UMOD mutations diagnosed in the genetic laboratories of Necker Hospital (Paris, France) and of Université Catholique de Louvain (Brussels, Belgium). We also analyzed patients with MCKD/FJHN but no UMOD mutation. To determine thresholds for hyperuricemia and uric-acid excretion fraction (UAEF) according to GFR, these parameters were analyzed in 1097 patients with various renal diseases and renal function levels.
Thirty-seven distinct UMOD mutations were found in 109 patients from 45 families, all in exon 4 or 5 except for three novel mutations in exon 8. Median renal survival was 54 years. The type of mutation had a modest effect on renal survival, and intrafamilial variability was high. Detailed data available in 70 patients showed renal cysts in 24 (34.3%) of nonspecific localization in most patients. Uricemia was >75th percentile in 31 (71.4%) of 42 patients not under dialysis or allopurinol therapy. UAEF (n = 27) was <75th percentile in 70.4%. Among 136 probands with MCKD/FJHN phenotype, UMOD mutation was found in 24 (17.8%). Phenotype was not accurately predictive of UMOD mutation. Six probands had HNF1B mutations.
Hyperuricemia disproportionate to renal function represents the hallmark of renal disease caused by UMOD mutation. Renal survival is highly variable in patients with UMOD mutation. Our data also add novel insights into the interpretation of uricemia and UAEF in patients with chronic kidney diseases.
UMOD 突变导致家族性青少年高尿酸血症性肾病 (FJHN) 和髓质囊性肾病 (MCKD),尽管这些表型不具有特异性。
设计、设置、参与者和测量方法:我们回顾了在法国巴黎 Necker 医院 (Necker Hospital) 和比利时布鲁塞尔天主教鲁汶大学 (Université Catholique de Louvain) 的遗传实验室诊断出的 UMOD 突变病例。我们还分析了没有 UMOD 突变但患有 MCKD/FJHN 的患者。为了根据肾小球滤过率 (GFR) 确定高尿酸血症和尿酸排泄分数 (UAEF) 的阈值,我们分析了 1097 例不同肾脏疾病和肾功能水平的患者的这些参数。
在 45 个家族的 109 名患者中发现了 37 种不同的 UMOD 突变,所有突变均位于外显子 4 或 5,除了 3 种位于外显子 8 的新突变。中位肾脏存活率为 54 年。突变类型对肾脏存活率的影响较小,家族内变异性较大。在 70 名患者的详细数据中,24 名 (34.3%) 患者的肾脏囊肿无特异性定位。42 名未接受透析或别嘌醇治疗的患者中有 31 名 (71.4%) 血尿酸 >75 百分位。27 名患者的 UAEF(n = 27) <75 百分位 70.4%。在 136 名具有 MCKD/FJHN 表型的先证者中,发现 UMOD 突变 24 例 (17.8%)。表型不能准确预测 UMOD 突变。6 名先证者有 HNF1B 突变。
与肾功能不成比例的高尿酸血症代表了 UMOD 突变引起的肾脏疾病的标志。UMOD 突变患者的肾脏存活率差异很大。我们的数据还为慢性肾脏病患者尿酸和 UAEF 的解释提供了新的见解。